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Prenatal Susceptibility to Carcinogenesis
by Xenobiotic Substances Including
Vinyl Chloride
by Jerry M. Rice*
The carcinogenicity of vinyl chloride for experimental animals when administered transpla-
centally is reviewed in comparison with known transplacental carcinogens, includingthose that,
like vinyl chloride, are dependent on enzyme-mediated metabolic conversion to a reactive
intermediate in maternal or fetal tissues. Vinyl chloride is converted by mixed-function oxidases
to the reactive metabolite chlorooxirane, the carcinogenicity of which is also reviewed. Vinyl
chloride is unequivocally atransplacental carcinogen forthe rat. No evidence exists, however, to
support the hypothesis that exposure of male rats to vinyl chloride or any other carcinogen
confers an increased risk of tumor development on their progeny. Many structural analogs of
vinyl chloride, i.e., substituted ethylenes, are also carcinogenic for adult animals, and can with
confidence likewise be predicted to be effective transplacental carcinogens.
Introduction
The carcinogenicity of vinyl chloride and its
predilection for the hepatic blood vessels of both
experimental animals and man is now well recog-
nized, and the substance is rightly regarded as a
serious hazard in the workplace. Moreover, the
demonstration by Maltoni (1) that vinyl chloride is
not only carcinogenic for adult rodents but is a
transplacental carcinogen for the rat as well, has
raised concern over apossible risk ofcarcinogenesis
in children born to mothers who had been employed
in vinyl chloride manufacturing during their preg-
nancy. In the United States this has also led to
questions of whether it is reasonable to single out
women in the workplace as individuals especially at
risk and whether to do so unfairly infringes upon
their rights to equality in employment. It has been
asked whether men may not equally be at risk in
terms of the potential of workplace exposure to
vinyl chloride and related compounds to cause
genetic damage in workers so exposed, and in this
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indirect way to contribute to an increased risk of
cancer in their offspring. These are important
questions, not all ofwhich can be fully answered at
the present time. Our laboratory has not been
engaged in research on vinyl chloride and there-
fore can contribute no new data to what has been
presented during the course of this conference.
However, we have been engaged for many years in
studying the phenomena ofprenatal carcinogenesis
by a variety of chemical carcinogens and in species
as diverse as the mouse and subhuman primates,
and it is the purpose ofthis presentation to provide
a context of current knowledge about the phenom-
ena ofprenatal carcinogenesis within which the risk
of prenatal exposure to this agent and related
compounds can be evaluated.
Mechanisms of Chemical
Carcinogenesis
When one tests a substance or a mixture of
substances for carcinogenic activity in rodents, a
positive result commonly takes one or more of the
following three forms: (1) a higher incidence of
tumors of one or more organ systems is observed
179among treated animals in comparison with controls;
if several different doses have been administered,
test animals receiving higher dosage levels (except
at very high, toxic levels) have ahigherincidence of
tumors than test animals receiving lower dosage
levels; (2) a higher multiplicity oftumors occurs in
one or more organ systems in treated versus
control animals; if more than one dosage level is
given to different groups oftest animals, multiplici-
ty, like tumor incidence, also varies in rough
proportion to dose, and animals that receive the
highest nontoxic dosage regimen develop the high-
est multiplicity oftumors; (3) the latency fortumor
development is shortened in test animals that
develop tumors in comparison with control animals
that develop the same tumors; this effect also may
beproportional to dose, sothat animals thatreceive
thehighestdosage oftestcompound developtumors
after the shortest period oftime fromthe beginning
oftreatment. The results ofa bioassay by itselfcan
only assert that a substance indeed is carcinogenic,
in the purely phenomenological sense of the term,
by one or more of the above criteria. A bioassay
says nothing about the mechanism by which carci-
nogenesis has been effected. This is a significant
point, as evidence is steadily accumulating that not
all of the extremely diverse agents capable of
inducing tumors in animals or man act by the same
mechanism.
There exist a wide variety of chemicals that by
these criteria htave been shown to have the capacity
to induce tunmors in animals. These agents are
extremely diverse in their chemical features, and
include certain heavy metal cations; mineral fibers
suchasasbestos; andorganicpolymers, bothsoluble
(iron-dextran; DEAE-dextran) and insoluble, such
as plastic films. By far the greatest number of
known substances carcinogenic for man or animals,
however, are small organic molecules. For the
overwhelming majority of these carcinogens there
is a common mechanism ofaction. Agents belonging
to this class either react chemically, or are trans-
formed in the course ofmetabolism to products that
react chemically with intracellular nucleophiles,
including nucleic acids, to form covalent bonds.
Suchreactions areirreversible, andproceedthrough
the intermediate formation ofan electropositive, or
electrophilic, intermediate (2). Agents of this sort
react with DNA to induce mutations and can be
detected by their capacity to induce nonscheduled
DNA repair synthesis in nondividing cells; the term
"genotoxic" is becoming accepted as a descriptive
term for agents ofthis class, to which vinyl chloride
belongs.
Most genotoxic carcinogens are not themselves
chemically reactive and require metabolic trans-
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formation to a chemically reactive metabolite or
ultimate carcinogen. Although there exist a vari-
ety of mechanisms involving different enzyme sys-
tems by which such changes can be effected, the
most common route, which is applicable to vinyl
chloride, involves the mixed function oxidases (3).
This is a class of cytochrome-containing enzymes,
dependent on molecular oxygen and reduced nico-
tinamide-adenine dinucleotide phosphate (NADPH),
which have very broad substrate specificities and
are capable of catalyzing a variety of reactions,
including the epoxidation of carbon-carbon double
bonds, theoxidationofaromaticcompoundsthrough
the formation of arene oxides, and the oxidative
dealkylation ofcompounds such as nitrosamines by
hydroxylation of carbon atoms alpha to a nitrogen
or oxygen atom. The capacity of these enzyme
systems to metabolize different classes of foreign
substances, including chemical carcinogens, varies
from individual to individual and from tissue to
tissue, and is in part responsible for variation
among individuals and from one organ system to
another in susceptibility to different types ofchem-
ical carcinogens.
Transplacental Carcinogenesis
in Experimental Animals
To demonstrate transplacental carcinogenesis,
experiments must be designed to eliminate the
possibility of exposure to a chemical carcinogen by
any route other than across the placenta. For rats
and mice, in which species most such experiments
have been carried out, this is usually accomplished
byallowingthe carcinogen-treated, timed pregnant
female to deliver her young on top of a wire mesh
screen so that the pups, as they are delivered, fall
through the mesh into a cage below which is
inhabited by a lactating female. With luck, the
latter will gather up the newborns and care for
them as her own, raising them to maturity without
their having come postnatally into contact with
their carcinogen-contaminated natural mother. For
mice, such screens are generally made of 1/2 in.
hardware cloth; for rats, poultry fencing generally
proves adequate.
General features of experimental transplacental
carcinogenesis have been reviewed (4-6). The peri-
ods of susceptibility to different types of transpla-
cental toxic effects in rodents by chemical carcino-
gens are strictly related to stages of prenatal
development. Exposureduringtheintervalbetween
conception and implantation of the blastocyst will
either be without effect or will be embryocidal.
Exposure of rats and mice to the same agent
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implantation of the blastocyst and development of
the true placenta, when embryogenesis is occurring
with great rapidity, may be lethal to the conceptus;
at nonlethal doses there may be severe develop-
mental abnormalities. At lower dosage levels, in
the range ofexposures that are carcinogenic during
later periods ofdevelopment, tumors are generally
not induced in offspring of animals exposed to
carcinogens during this period even though their
life expectancy is not significantly shorter than that
ofuntreated offspring. After day 12, however, and
usually with increasing efficiency thereafter until
termination of pregnancy, exposure of a gravid
female to a carcinogen will cause tumors to develop
in her offspring. Tumors develop in different organ
systems in different species in response to a given
agent, but are generally at least in part morpholog-
ically and anatomically similar to those inducible by
postnatal exposure to the same agent. A given
agent may not affect a given tissue or organ
similarly in all species, and the tumor spectrum
seen as a consequence of prenatal exposure may
vary markedly from one species to another.
The most potent transplacental carcinogens are
direct-acting alkylating agents, which, like methyl-
nitrosourea (Fig. 1), decompose to reactive inter-
mediates without enzymatic catalysis. The next
higher homolog ofthis compound, ethylnitrosourea
(ENU), is extremely active transplacentally and
has been extensively studied in both rodent and
nonrodent species. When this compound is adminis-
tered as a single injection to a pregnant rat on one
ofthe first 11 days ofgestation, high doses result in
devastating teratogenic effects or in death of the
embryo, but not in tumorigenesis in surviving
offspring. Beginning on day 12 and with increasing
efficiency thereafter the offspring, which appear
normal at birth ifdosage is kept at a level below the
acutely toxic range, subsequently develop tumors
ofthe central and peripheral nervous system, with
overt signs of disease developing 2 months to 2
years after birth (7). All three of the parameters
previously mentioned as indices of carcinogenicity
can be observed in experiments with ENU; the
incidence of tumors and the multiplicity of tumors
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ofthe nervous system in treated offspring are both
directly proportional to the dose administered to
the mother, while latency is inversely proportional
to dose. Despite the fact that ENU is a direct
acting agent and is distributed nearly uniformly
throughout the tissues of the rat fetus, tumors
rarely appear in organ systems other than the
nervous system. Occasionally, tumors ofthe kidney
are seen, and an occasional offspring may develop
leukemia. Epithelial tumors of the liver and the
lung, for example, are virtually never encountered
in rats transplacentally exposed to ENU.
When one compares the dose-response relation-
ships for offspring of rats treated on day 15 of
gestation with the response of adult rats to the
same agent, it is found that the offspring are
approximately 50-fold more susceptible than adults
to the carcinogenic effects of this agent: the dose
necessary to induce one ormore neurogenic tumors
in 50% of exposed adult rats is on the order of 150
mg/kg, but the corresponding dose for transplacen-
tally exposed offspring is approximately 3 mg/kg
(calculated on the basis of the mother's total body
weight).
If exactly the same sort of experiment is con-
ducted in the mouse, however, the results are
qualitatively much different. Tumors of the ner-
vous system are relatively rare in mice following
transplacental exposure to ENU. As in rats, how-
ever, transplacentally treated offspring exposed on
or after day 12 of gestation develop tumors. In
contrast to rats, mice exposed transplacentally to
ENU develop epithelial tumors of the lung and
hepatocellular tumors ofthe liver in high incidence
and multiplicity (8). In both species, the fetus is
quantitatively more susceptible than the adult:
susceptibility is greatest during the second half of
the period of gestation, and increases as gestation
proceeds towards parturition. Adult animals are
less sensitive, by one to two decimal orders of
magnitude, to the carcinogenic effects of ENU.
This much higher prenatal susceptibility is one of
the principal reasons for concern that transplacen-
talexposuretocarcinogensinthemother'sworkplace
or environment may be of significant risk for the
human fetus.
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FIGURE 1. Decomposition of methylnitrosourea to yield a reactive alkylating diazonium'hydroxide product. The initial step is
pH-dependent, but does not require enzyme-mediated catalysis.
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laboratories have shown, however, that two sig-
nificant differences from the patterns of response
seen in rodents occur when transplacental carcino-
genesis experiments are carried out in a nonhuman
primate. Different tissues are affected by the
carcinogen, and the period of greatest prenatal
susceptibility is early rather than late in gestation.
Experiments on transplacental carcinogenesis in
the Old World monkey, Erythrocebus patas, whose
gestation period averages 170 days, have clearly
shown that ENU is a transplacental carcinogen for
this primate (9), but that it causes tumors princi-
pally of the vascular connective tissues and to a
lesser extent the liver, kidney and brain, a pattern
of response different from either the rat or the
mouse. Tumor incidence is higher and latency is
shorter in offspring than in pregnant or nonpreg-
nant treated adults; in that respect the pattern
resembles that seen in both rodent species, but
neither the rat or the mouse yields a spectrum of
tumors predictive of the results of exposing mon-
keystothesameagent. Inourexperimentspregnant
patas monkeys were exposed to ENU during either
the first half or the second half of gestation, or
throughout pregnancy. It has become strikingly
apparent that animals exposed for the first time at
day 30 are at much higher risk for tumor develop-
ment than animals given comparable exposure but
beginning even 30 days later in gestation. This
marks a significant departure from the patterns
seen in rodents and suggests that the period of
maximum intrinsic susceptibility to chemical car-
cinogens in other primates, including man, may
well be during the first trimester ofpregnancy and
in that respect may resemble the period ofgreatest
susceptibilitytoteratogens. Obviously, thisincludes
the early fraction ofgestation during which, at the
time of possibly greatest vulnerability of her con-
ceptus, a woman may not know for certain that she
is pregnant and may therefore not be warned to
take special precautions to prevent exposure to
noxious agents.
In other important respects, such as the greater
susceptibility of the fetus, experience in the patas
monkey is comparable to that in the rat and mouse
and suggests that the phenomenon of high fetal
susceptibility to carcinogens is a general one. The
fact that the organ systems principally affected by
ENU in this species are different from those ofthe
rodent species further emphasizes that one should
be extremely cautious in extrapolating from any
other species to man in predicting the site ofaction
of a chemical carcinogen, even a direct acting one.
The one common pattern valid across species lines
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in the matter of prenatal organ specificity is that
the nervous system and the kidneys appear to be
susceptible to at least some extent to this agent in
all species tested, an observation which brings to
mind the factthat tumors ofthe kidneyand nervous
systempredominate amongsolid tumors ofchildhood.
Transplacental Carcinogenesis by
Metabolism-Dependent Carcinogens
The vast majority of genotoxic chemical carcino-
gens are not direct-acting, but, as indicated pre-
viously, require metabolic conversion to a chemi-
cally reactive ultimate carcinogen in order to effect
carcinogenesis. It has been shown that in rodents,
the mixed function oxidase enzymes principally
involved in activation of chemical carcinogens are
present at low or virtually undetectable levels in
fetal tissues until immediately prior to parturition,
and even then are present at levels that are minus-
cule in comparison with those in adult tissues (10).
The picture is complicated by the fact that these
enzymes are inducible, and their levels in tissues
such as the liver may be significantly altered by
exposure to chemical agents that are substrates for
these enzymes, including carcinogens such as methyl-
cholanthrene (3). The role of enzyme induction in
modifying fetal susceptibility to transplacental carcin-
ogens has not yet been well studied and remains
conjectural. However, the low levels of enzymes
present in noninduced fetal rodent tissues result in
extremely inefficient conversion ofmost substances
toreactive ultimate carcinogenicmetabolites. Thus,
when the chemically reactive metabolite is very
unstable, i.e., has an extremely short half-life under
physiologic conditions, it cannot be effectively gen-
erated in maternal tissues and transported viamater-
nal and fetal- bloodstreams to fetal tissues. Very
short-lived reactive metabolites must be generated
in situ in any fetal tissue in which carcinogenesis is
to occur. Agents whose carcinogenicity is mediated
by such metabolites are extremely poor transpla-
cental carcinogens. An example is dimethylnitro-
samine (DMN; Fig. 2). DNM is metabolized by mixed
function oxidases bytheN-dealkylation mechanism,
generating an intermediate methyl(hydroxymethyl)-
nitrosamine whichisfartoounstabletodemonstrate
evenspectroscopically. Ithasneverbeen synthesized.
This is an excellent example of an agent which
presumably must be formed byfetalenzymes. When
the parent compound, DMN, was tested for trans-
placental carcinogenic activity it was found as
expected to be much less efficient in offspring than
in their mothers in the induction of tumors of the
kidney (11).
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FIGURE 2. Metabolic activation of dimethylnitrosamine by a mixed-function oxidase (MFO) to a reactive intermediate formally
equivalent to that generated nonenzymatically from methylnitrosourea as diagrammed in Figure 1. The enzyme catalyzed
N-demethylation reaction requires molecular oxygen and NADPH, and yields a product too unstable and short-lived to isolate or
synthesize.
From the example of dimethylnitrosamine, one
might be tempted to infer that the transplacental
route of exposure is insignificant for metabolism-
dependent carcinogens and, since this encompasses
the vast majority ofgenotoxic carcinogens, is not a
significant route ofhuman exposure. Such a predic-
tion is probably wrong. Proximate and ultimate
carcinogenic metabolites ofmany metabolism depen-
dent carcinogens are much more stable than methyl-
(hydroxymethyl)nitrosamine. An excellent example
is afforded by the polynuclear aromatic hydrocar-
bons, especially 7,12-dimethylbenz[a]anthracene
(DMBA, Fig. 3) which in common with many ofthe
othercarcinogenic substances belongingtothischem-
ical class can undergo metabolism to a variety of
chemically reactive, arene oxide metabolites which
are all ultimate carcinogens of varying potency.
The most carcinogenic metabolites of this type of
compound are the bay region diolepoxides (12),
formed by three sequential metabolic steps as indi-
cated in Figure 3. The arene oxides, dihydrodiol,
and diolepoxide (Fig. 3) have all been synthesized
and are sufficiently stable for not only synthesis and
characterization, but for direct testing of carcino-
EH .
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FIGURE 3. Some mixed-function oxidase reactions of the poly-
nucleararomatichydrocarbon7,12-dimethylbenz[a]anthracene
(DMBA), yielding various mutagenic arene oxide products.
These may subsequently be hydrolyzed by epoxide hydratase
(EH) to dihydrodiols, which in turn may serve as substrates
for MFO reactions that yield diolepoxides. Although carcino-
genic and very reactive, diolepoxides can be synthesized.
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genic potency in experimental animals (13, 14).
Accordingly, it is quite possible that metabolites of
this sort may be formed in maternal tissues and
may succeed intraversingthematernalbloodstream
and placenta to reach the fetus. When the parent
hydrocarbon DMBA was tested for transplacental
carcinogenicity in rats by using a foster nursing
procedure (15), itwasfoundtobe extremelypotent.
The experiment was terminated at 52 weeks with
only 20% ofthe offspring still surviving; large num-
bers oftumors were seen in the central and periph-
eral nervous systems, the kidneys, and blood ves-
sels, as well as in other sites. Thus, not only is this
particular metabolism dependent agent a potent
transplacental carcinogen, but it actually affects a
broader spectrum of organ systems in the fetus of
the rat than the extremely potent direct acting
carcinogen ENU.
Metabolism and Carcinogenicity of
Vinyl Chloride
The carcinogenicity of vinyl chloride for rats,
mice, and hamsters over an extremely wide range
of doses as well as its transplacental carcinogenic
effects in rats, are presented by Maltoni (16); an
earlier version ofhis datafor rats (1) is summarized
in Table 1. It can be seen that on inhalation ofvinyl
chloride, tumors are induced in dose-dependent
fashion in adult rats in the liver, nasal cavity,
kidneys, Zymbal's gland, and most importantly and
consistently, in the blood vessels, especially those
ofthe liver. Transplacental exposure for aperiod of
one week, between the 12th and 18th days ofpreg-
nancy, generated tumors in three ofthe,se tissues,
the kidney, blood vessels, and Zymbal's gland, in
the offspring (Table 2). Although no controls were
included specifically in thetransplacental study, the
very large series ofhistorical control animals care-
fully examined in that laboratory are convincing
proofthat the elevated incidence oftumors ofthese
three tissues is real, and that vinyl chloride is ef-
fectively a transplacental carcinogen in the rat. It
is noteworthy that the sites and kinds oftumors in-
183duced by vinyl chloride are different in part from
those that resulted from transplacental exposure to
any of the agents discussed previously, none of
which affected the Zymbal's glands. The tissues
and organs affected in offspring exposed transpla-
centally to vinyl chloride included some but not all
those in which tumors developed in adults subjected
to much more prolonged exposures (cf. Tables 1 and
2), and in the transplacental study, significant num-
bers oftumors were induced in the offspring but not
in the mothers.
Vinyl chloride is a metabolism-dependent carcin-
ogen, dependent for its carcinogenicity on mixed
function oxidases (17) which convert vinyl chloride
toits epoxide derivative chloroethylene oxide (chlor-
ooxirane, Fig. 4). The carcinogencity ofchloroethyl-
ene oxide and ofits rearrangement product, chloro-
acetaldehyde, wererecentlyinvestigated byresearch-
ers at the International Agency for Research on
Cancer in Lyon, France, who tested both com-
pounds by subcutaneous injection and by skin paint-
ing, the latter followed by phorbol ester promotion,
in mice. Chloroethylene oxide proved to be an
effective carcinogen, inducing both papillomas and
carcinomas in the skin and giving rise to sarcomas
on injection (Table 3). Its rearrangement product,
chloroacetaldehyde, was toxic, but not demonstra-
bly carcinogenic (18). It was noted by the IARC
investigators is that the half-life of chloroethylene
oxide for hydrolysis at 370 C is on the order of 0.9
min. This is sufficient time for chloroethylene oxide
formed in maternal tissues to reach the fetus by
way of the placenta, and provides strong sugges-
tive evidence that maternal metabolism contributes
to transplacental carcinogenicity of vinyl chloride.
To date, however, chloroethylene oxide has not
itselfbeen tested for transplacental carcinogencity.
Analogs of Vinyl Chloride
It is important to note that vinyl chloride is by no
means unique with respect to chemical structure,
and that a wide variety ofcompounds are in current
use in large volumes in industrial processes which
differ from vinyl chloride only by further substitu-
tion of the vinyl chloride molecule. A partial list of
such substances is given in Table 4. Furthermore
Table 1. Tumors in Sprague-Dawley rats after inhalation exposure to vinyl chloride, 4 hr daily and 5 days weekly for 52 weeks.
Partial results after 135 weeks.a
Rats with tumors
Rats at Zymbal's Angiosarcoma Liver
risk gland Nephro- cell Nasal
Vinyl chloride, ppm (both sexes) carcinoma blastoma Liver Other tumors cavityb
30,000 60 35 0 18 1 1 1
10,000 69 16 5 9 3 1 7
6,000 72 7 4 13 3 1 3
2,500 74 2 6 13 3 2 5
500 67 4 4 7 2 3 0
250 67 0 6 4 2 0 0
50 64 0 1 1 1 0 0
None 68 0 0 0 0 0 0
aData from Maltoni (1).
bOriginally reported (1) as neuroblastoma of the brain.
Table 2. Tumors in female Sprague-Dawley rats exposed tovinyl chloride by inhalation 4 hrdaily from day 12 through day 18 of
gestation, and in their offspring.a
Rats with tumors after 115 weeks
Vinyl chloride Rats exposed Zymbal'sgland Nephro- Angiosarcoma
Generation concentration (ppm) Total Survivors carcinoma blastoma Liver Other
Parents 10,000 30 30 1 0 0 1
6,000 30 30 0 0 0 0
Offspring 10,000 54 12 3 1 0 2
6,000 32 8 1 0 0 2
aData from Maltoni (1).
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FIGURE 4. Metabolism ofvinylchloride bymixedfunction oxidases tochlorooxirane, acarcinogenic substancethatisstableenoughto
synthesize.
Table 3. Carcinogenicity of chloroethylene oxide in adult mice.a
Effective number Route Tumor-bearing animals, Duration of experiment,
% days
28 M 32 SC injections 15 (54) 549
24 F 12 (50) 549
Control
30 M 0 (0) 549
28 M 1 mg initiation (skin); TPA promotion 26 (93), papillomas 590
5 (18), carcinomas
Control
28 M 4 (15), papillomas 590
0, carcinomas
aData from Zajdela et al. (18).
Table 4. Carcinogenicity in adult rodents of structural analogs ofvinyl chloride reviewed in the IARC Monograph Series.
Site of lesions
Compound Structure Reference Rats Mice
Vinyl chloride CH2=CHCl (22a) Angiosarcoma Angiosarcoma
Zymbal's gland Lung
CNS Mammary
Kidney
Vinylidene chloride CH2=CC12 (22b) Similar to vinyl chloride, but incomplete in 1979
Trichlorethylene CHCI= CC12 (23a) (Inadequate) Lung, liver
Tetrachlorethylene CCl2=CC12 (23b) Negative Liver
Chloroprene CH2=CH-CCl=CH2 (22c) Inadequate
there is an even larger list ofsubstances that resem-
ble vinyl chloride in that they are substituted deriv-
atives of ethylene, but differ in that they lack a
chlorine atom. A very brieflist ofimportant deriva-
tives ofthis sort is given in Table 5. A much longer
list is given in the review by Posner and Falk (19).
It is reasonable to postulate that metabolism via
reactive epoxides is one route of metabolism to be
expected for all these compounds, and mutagenic
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metabolites of some of them have been demon-
strated (20, 21). If mutagenic epoxides are formed
in significant quantities in maternal tissues and are
chemically reactive, yet stable enough to reach the
fetus, it is probable that they too would have some
measureoftransplacentalcarcinogenicactivity. Some
ofthe substances listed in Tables 4 and 5 have been
reviewed for risk of carcinogenicity to man in the
IARC monograph series (22, 23). Other compounds
185Table 5. Compounds structurally similar to vinyl chloride that may have similar carcinogenic activity.
Site of lesion
Compound Structure Reference Rats Mice
Vinyl bromide CH2=CHBr Not yet reviewed
Styrene Ch2=CHC6H5 (22d) - Lung (?)
Acrylonitrile CH2=CHCN (22e) Brain
Forestomach
Zymbal's gland
Acrylamide CH2=CHCONH2 Not yet reviewed
Ethyl acrylate CH2=CHCOOC2H5 Not yet reviewed
listed here have beentested in the United States by
the National Cancer Institute-National Toxicology
Program. As a significant number have been found
to be carcinogenic in at least one rodent species, it
is reasonable to regard the entire class with suspi-
cion as possible potential carcinogens and transpla-
cental carcinogens pending the acquisition of fur-
ther data.
Effects of Transplacental
Carcinogens on Subsequent
Generations: Lack of Male
Parental Risk for
Prenatal Carcinogenesis
In the context of our present knowledge, prena-
tal carcinogenesis is virtually synonymous with trans-
placental carcinogenesis. That is, there is very little
evidence to indicate that exposure ofeither male or
female parents to a chemical carcinogen prior to
conception confers an increased risk of carcinogen-
esis on their offspring. It should be pointed out that
carcinogenic risk is not the only risk, and that
exposure of males to toxic agents may cause steril-
ity or reduce fertility. In rodents it has also been
shown that dominant lethal mutations may be induced
in this manner, the consequence ofwhich is death of
the conceptus (24). These hazards however are
different from carcinogenic risk for surviving off-
spring, which has not been shown to be a conse-
quence ofexposure ofadult males orofadultfemales
prior to conception.
The experimental data which are relevant to this
question generally concern what has been termed
the "second generation effect" in prenatal carcino-
genesis, which has been reviewed by Tomatis (25).
The general design ofexperiments ofthis sort is as
follows: The female of a parental generation, P, is
given achemicalcarcinogenduring pregnancy. Male
and female offspring of the treated female, consti-
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tuting the F1 generation, are then at risk for trans-
placental carcinogenesis. On attaining sexual matu-
rity, andbeforetumorsresultingfromtransplacental
exposure appear, F1 males and females are mated
to produce an F2 generation. Both parents ofthe F2
generation had been exposed to carcinogen during
prenatal life, but at no time were the F2 animals
exposed. Inaddition, males oftheprenatallyexposed
F1 generation were bred with untreated females to
produce offspring designated F2M, whose male
parents only had been subjected to chemical car-
cinogens. Likewise, the F1 females were bred with
untreated controlmalestoproduceaF2Fgeneration,
of which only female parents had experienced
exposure to chemical carcinogens. Similar experi-
ments have been continued to the third and higher
generations in attempts to demonstrate a higher
incidence of tumors in comparison with untreated
controls. Such experiments have been carried out
with polynuclear aromatichydrocarbons, directact-
ing nitrosourea carcinogens, and with ethyl carba-
mate, in three laboratories. They have consistently
demonstrated that a small, often statistically in-
significant but nevertheless reproducible and per-
sistent excess risk ofcarcinogenesis is present in F2
and F2F generations. F2M offspring in general
have shown no excess risk. The numbers oftumors
observed in the second generations in experiments
of this sort have invariably been extremely small,
leaving much to be desired in terms of statistical
significance. However, these studies constitute the
only experimental evidence for a chemically induced
enhanced susceptibility to cancermediated by dam-
age to the germ cells. Present evidence indicates
that ifthis effect is real, it is most significant forthe
femalegermcells, whichareundergoingrapidmitotic
division during the final week ofintrauterine devel-
opment in the female rat or mouse fetus.
On the basis ofpresent information, therefore, it
is clearthat prenatal carcinogenesis by chemicals is
principally a direct effect ofchemicals or their fetal
or maternal metabolites upon fetal tissues, rather
than upon the germ cells of the parents of either
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germ cells exists, that damage with its attendant
increased risk of carcinogenesis in the offspring
appears greatest whenthe female parent isexposed
to a carcinogen; and that the fetus is at risk on
account ofmaternal exposures to potential carcino-
gens, not only because it is inevitably exposed to
any agent that may find its way into the maternal
bloodstream, but also because carcinogenic or toxic
metabolites which may be even more dangerous
than the environmental precursor may be gener-
ated by maternal tissues and transferred via the
placenta to the fetus.
The incidence of tumors that will develop in a
given organ system following transplacental expo-
sure to a carcinogen is not necessarily the maxi-
mum incidence possible. Cocarcinogenic phenome-
na, in which exposure to a second, noncarcinogenic
agent accelerates the development and increases
the yield oftumors resulting from a previous carci-
nogenic exposure, are well demonstrated in trans-
placentalcarcinogenesis (26), especiallyinthemouse
where they have been documented for the skin and
for the liver. Potential tumor cells may remain
quiescent for prolonged periods after exposure to
theinducingagent, and inevaluatingthesignificance
of transplacental exposure one must bear in mind
that subsequent, postnatal exposure to noncarcino-
genic promoting agents may act in a strongly syn-
ergistic fashion with prenatal exposure to a carcin-
ogen and may greatly increase the risk of carcino-
genesis.
Finally, all agents known to be prenatal-that is,
transplacental-carcinogens are also carcinogenic
to some extent during postnatal life in one or more
species. To some extent, this is a consequence of
the manner in which the science of transplacental
carcinogenesis has developed; known carcinogens
have been selected for testing for transplacental
effects. Nonetheless, the generalization holds that
thereis no knownpurelytransplacental carcinogen.
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